IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 75.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-08-14
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-06-30 was 75.00K shares.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2025-12-31 was 70.00K shares, a 133.33% increase year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2025-09-30 was 10.00K shares.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2025 was 212.00K shares, a 26.90% decline from fiscal 2024.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 290.00K shares, a 18.37% increase from fiscal 2023.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 245.00K shares, a 807.41% increase from fiscal 2022.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 27.00K shares, a 87.73% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2026-06-30 | 75.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 75.00K shares 10-Q · filed 2026-08-14 | 145.00K shares derived: sum of 3 quarters · filed 2026-08-14 | 155.00K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | 70.00K shares derived: sum of 2 quarters · filed 2026-05-15 | 80.00K shares derived: sum of 3 quarters · filed 2026-05-15 | 80.00K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 70.00K shares derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18 | 80.00K shares derived: sum of 2 quarters · filed 2026-03-18 | 80.00K shares 10-KT · filed 2026-03-18 | 262.00K shares derived: sum of 4 quarters · filed 2026-03-18 |
| 2025-09-30 | 10.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | 10.00K shares 10-Q · filed 2025-11-14 | 192.00K shares derived: sum of 3 quarters · filed 2025-11-14 | 222.00K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2025-08-14 | 182.00K shares derived: sum of 2 quarters · filed 2025-08-14 | 212.00K shares derived: sum of 3 quarters · filed 2025-08-14 | 212.00K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 182.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27 | 212.00K shares derived: sum of 2 quarters · filed 2025-06-27 | 212.00K shares derived: sum of 3 quarters · filed 2025-06-27 | 212.00K shares 10-K · filed 2025-06-27 |
| 2024-12-31 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-14 | 30.00K shares derived: sum of 2 quarters · filed 2025-02-14 | 30.00K shares 10-Q · filed 2025-02-14 | 320.00K shares derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | 0.00 shares 10-Q · filed 2024-11-12 | 290.00K shares derived: sum of 3 quarters · filed 2024-11-12 | 290.00K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-07 | 290.00K shares derived: sum of 2 quarters · filed 2024-08-07 | 290.00K shares derived: sum of 3 quarters · filed 2024-08-07 | 290.00K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 290.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24 | 290.00K shares derived: sum of 2 quarters · filed 2024-06-24 | 290.00K shares derived: sum of 3 quarters · filed 2024-06-24 | 290.00K shares 10-K · filed 2024-06-24 |
| 2023-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-02-14 | 0.00 shares 10-Q · filed 2024-02-14 | 245.00K shares derived: sum of 4 quarters · filed 2024-02-14 |
| 2023-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | 0.00 shares 10-Q · filed 2023-11-09 | 245.00K shares derived: sum of 3 quarters · filed 2023-11-09 | 245.00K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-10 | 245.00K shares derived: sum of 2 quarters · filed 2023-08-10 | 245.00K shares derived: sum of 3 quarters · filed 2023-08-10 | 245.00K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 245.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-07 | 245.00K shares derived: sum of 2 quarters · filed 2023-07-07 | 245.00K shares derived: sum of 3 quarters · filed 2023-07-07 | 245.00K shares 10-K · filed 2023-07-07 |
| 2022-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-14 | 0.00 shares derived: sum of 2 quarters · filed 2023-02-14 | 0.00 shares 10-Q · filed 2023-02-14 | 0.00 shares derived: sum of 4 quarters · filed 2023-02-14 |
| 2022-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-01 | 0.00 shares 10-Q · filed 2022-11-01 | 0.00 shares derived: sum of 3 quarters · filed 2022-11-01 | 0.00 shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-05 | 0.00 shares derived: sum of 2 quarters · filed 2022-08-05 | 0.00 shares derived: sum of 3 quarters · filed 2022-08-05 | |
| 2022-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | 0.00 shares derived: sum of 2 quarters · filed 2022-06-23 | 27.00K shares 10-K · filed 2022-06-23 | |
| 2021-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-10 | 27.00K shares 10-Q · filed 2022-02-10 | ||
| 2021-09-30 | 27.00K shares 10-Q · filed 2021-10-29 | |||
| 2021-03-31 | 220.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14 | 220.00K shares derived: sum of 2 quarters · filed 2021-06-14 | 220.00K shares derived: sum of 3 quarters · filed 2021-06-14 | 220.00K shares 10-K · filed 2021-06-14 |
| 2020-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | 0.00 shares derived: sum of 2 quarters · filed 2021-02-16 | 0.00 shares 10-Q · filed 2021-02-16 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-20 | 0.00 shares 10-Q · filed 2020-11-20 | ||
| 2020-06-30 | 0.00 shares 10-Q · filed 2020-08-19 | |||
| 2020-03-31 | 0.00 shares 10-K · filed 2020-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |